Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
These compounded formulations are not reviewed or approved by the FDA
To enhance safety, existing guidance includes subcutaneous-only injections, limiting graft volume per session, experienced surgeons, ultrasound guidance in certain practices, and scrupulous patient selection
Timely access to a care team that can address these issues in the moment may help improve GLP-1 outcomes
Premised on our previously clinical evidence and recent breakthroughs in clinical therapy of A on C, we designed a new protocol with the combination of CHF and RG
The most common ones are gastrointestinal which makes sense, since these drugs work partly in the gut
RESEARCH AREAS Estrogen-related receptor alpha (ERR) agonism and receptor binding characterization Transcriptional regulation of mitochondrial biogenesis pathways (e.g., PGC-1 coactivation networks) Oxidative phosphorylation and fatty-acid oxidation gene-expression signaling Cellular energy-metabolism and substrate-utilization pathway modeling WHAT RESEARCHERS LOOK AT Receptor-binding and reporter-gene assays measuring ERR isoform engagement Dose-response transcriptional profiling of metabolic target genes in cell culture Mitochondrial density and respiration assays in isolated model systems Pathway-selectivity and off-target screening across nuclear-receptor panels QUICK SPECS Form: Capsule not for ingestion Net per capsule: 100mcg Count: 100 capsules per bottle Purity: 98% (HPLC) Identity: Confirmed by HPLC/MS Storage: Store sealed, cool, dry, protected from light IDENTITY BASICS Type: Synthetic small-molecule ERR agonist (non-peptide) Molecular formula: CHNO Molecular weight: ~445.5 g/mol CAS: 2231747-31-0 SELECTED RESEARCH PubChem: SLU-PP-332 compound record PubMed: SLU-PP-332 literature index PubMed: ERR agonist research PubMed: ERR/mitochondrial biogenesis signaling DISCLAIMER For laboratory and in vitro research use only
